THROMBOSIS AND BLEEDING COMPLICATIONS AFTER IMPLANTATION OF MECHANICAL CIRCULATORY SUPPORT DEVICES: THE REASONS AND MECHANISMS OF DEVELOPMENT, GENOME-GUIDED CORRECTION. REVIEW.
Introduction. This review is devoted about the development of the thrombosis and bleeding complications after implantation of the mechanical circulatory support (MCS) device in heart failure (HF) patients which could be treated by genotyping test results.
Objective. To analyze literature and clinical investigations about cause of the complications and their prevention by genome-guided antithrombotic therapy according to the genotyping test results for genetic polymorphisms.
Research strategy. Search for scientific publications was carried out in search engines such as Web of Science, ResearchGate, PubMed, Google Academy and e-Library.ru. Criteria for inclusion of publications in the literature review are defined as publications with the full text, in Russian and English, with statistically verified conclusions.
Results. Complications develop due to the presence of the high non-physiological shear stress at the blade region of the MCS device’s rotary. The shear stress causes platelet dysfunction which affects to normal hemostatic function. On the other hand, complications development occurs due to the antithrombotic therapy which could be prescribed with incorrect dosage for HF patients after device implantation. Nowadays, complications could be reduced by genome-guided antithrombotic therapy according to the genotyping test results for genetic polymorphisms of VKORC1, CYP2C9 and UGT1A6 genes which cause variability of drug dosage approximately for 50%.
Conclusions. The genotype polymorphisms of genes encoding enzymes which influence to the mechanism and activation of the antithrombotic drugs are necessary to be determined in HF patients as it will help to identify appropriate dosage of the drugs. The identified genome-guided antithrombotic therapy will help to reduce and predict thrombosis/bleeding complications at pre and post-MCS device implantation period which will give opportunity for patients to survive and live longer life.
Madina R. Zhalbinova1,2, https://orcid.org/0000-0001-9704-8913
Saule E. Rakhimova1, http://orcid.org/0000-0002-8245-2400
Kenes R. Akilzhanov3, https://orcid.org/0000-0002-3342-2424
Saltanat A. Andosova4, https://orcid.org/0000-0001-7259-183X
Makhabbat S. Bekbosynova4, https://orcid.org/0000-0003-2834-617X
Ainur R. Akilzhanova1,2, http://orcid.org/0000-0001-6161-8355
1 National Laboratory Astana, Nazarbayev University, Astana, Republic of Kazakhstan;
2 L.N. Gumilyov Eurasian National University, Astana, Republic of Kazakhstan;
3 Semey Medical University, Pavlodar Branch, Pavlodar, Republic of Kazakhstan;
4 National Research Cardiac Surgery Center, Astana, Republic of Kazakhstan
1. Бодаубай Р.И., Тайжанова Д.Ж. Генетические предиктoры рaзвития рестенoзa кoрoнaрных aртерий // West Kazakhstan Medical Journal. 2019. 61(3). С. 163-171.
2. Гринштейн Ю.И., Косинова А.А., Гринштейн И.Ю. Гены-кандидаты резистентности к ацетилсалици-ловой кислоте и их связь с риском развития сердечно-сосудистых катастроф // Кардиоваскулярная терапия и профилактика. 2013. T.12. № 1. С. 67-72.
3. Жалбинова М.Р., Рахимова С.Е., Бекбосынова М.С., Андосова С.А., Акильжанова А.Р. Причины и механизмы развития гематологических осложнений у пациентов с имплантированным механическим устройством левого желудочка // Наука и Здравоохранение. 2020. 22 (1). С. 5-16.
4. Жалбинова М.Р., Рахимова С.Е., Кожамкулов У.А., Бекбосынова М.С., Акильжанова А.Р. Патент № 35979. Способ подбора и коррекции дозы аспирина у больных сердечной недостаточностью с имплантированным механическим устройством левого желудочка. № 2021/07.21.1; заявл. 26.11.2021; опубл. 09.12.2022, Бюл. № 49.
5. Пя Ю.В., Бекбосынов С.Т., Бекбосынова М.С., Куатбаев Е.М., Лесбеков Т.Д., Калиев Р.Б., Джетыбаева С.К., Медресова А.Т., Нурмыхаметова Ж.А., Мурзагалиев М.У., и др. Программа трансплантации сердца в эпоху механической поддержки кровообращения: опыт Республики Казахстан // Журнал имени академика Б.В. Петровского Клиническая и экспериментальная хирургия. 2017. Том. 5. №3. С. 49-53.
6. Пя Ю.В., Бекбосынов С.Т., Бекбосынова М.С., Медресова А.Т., Андосова С.А., Джетыбаева С.К., Мурзагалиев М.У., Новикова С.П. Использование современных устройств механической поддержки кровообращения как альтернативы трансплантации сердца у пациентов с терминальной сердечной недостаточностью // Журнал имени академика Б.В. Петровского Клиническая и экспериментальная хирургия. 2017. Tом. 5. №1. С. 7-14.
7. Abuqayyas S., Raju S., Bartholomew J. R., Abu Hweij R., Mehta A.C. Management of antithrombotic agents in patients undergoing flexible bronchoscopy // Eur Respir Rev. 2017. 26(145). https://doi.org/10.1183/16000617.0001-2017
8. Agúndez J.A.G., Martínez C., Pérez-Sala D., Carballo M., Torres M.J., García-Martín E. Pharmacogenomics in Aspirin Intolerance // Current Drug Metabolism. 2009. Vol.10. P. 998– 1008.
9. Awad M., Czer L.S.C., Soliman C., Mirocha J., Ruzza A., Pinzas J., Rihbany K., Chang D., Moriguchi J., Ramzy D., Esmailian F., Kobashigawa J., Arabia F. Prevalence of Warfarin Genotype Polymorphisms in Patients with Mechanical Circulatory Support // ASAIO J. 2015. 61(4). P. 391-6. DOI: 10.1097/MAT.0000000000000231
10. Baumann Kreuziger L.M., Kim B., Wieselthaler G.M. Antithrombotic therapy for left ventricular assist devices in adults: a systematic review // J Thromb Haemost. 2015. 13(6). P. 946-955. DOI: 10.1111/jth.12948
11. Baumann Kreuziger L.M. Management of anticoagulation and antiplatelet therapy in patients with left ventricular assist devices // J Thromb Thrombolysis. 2015. 39(3). P. 337-344. DOI 10.1007/s11239-014-1162-6
12. Chen Y., Kuehl G.E., Bigler J., Rimorin C.F., Schwarz Y., Shen D.D., Lampe J.W. UGT1A6 polymorphism and salicylic acid glucuronidation following aspirin // Pharmacogenetics and Genomics. 2007. 17(8). P. 571–579.
13. Chen Z., Koenig S.C., Slaughter M.S., Griffith B.P., Wu Z.J. Quantitative Characterization of Shear-Induced Platelet Receptor Shedding: Glycoprotein Ibalpha, Glycoprotein VI, and Glycoprotein IIb/IIIa // ASAIO J. 2018. 64(6). P. 773-778. DOI: 10.1097/MAT.0000000000000722
14. Dean L. Warfarin Therapy and VKORC1 and CYP Genotype // Medical Genetics Summaries. 2018. P. 1-18.
15. Deconinck S.J., Nix C., Barth S., Bennek-Schopping E., Rauch A., Schelpe A. S., Roose E., Feys H. B., Pareyn I., Vandenbulcke A., Muia J., Vandenbriele C., Susen S., Meyns B., Tersteeg C., Jacobs S., De Meyer S.F., Vanhoorelbeke K. ADAMTS13 inhibition to treat acquired von Willebrand syndrome during mechanical circulatory support device implantation // J Thromb Haemost. 2022. 20 (12). P. 2797-2809. DOI: 10.1111/jth.15889
16. Hetzer R., Javier M. F. dM., Dandel M., Loebe M., Javier Delmo E.M. Mechanical circulatory support systems: evolution, the systems and outlook // Cardiovasc Diagn Ther. 2021. 11 (1). P. 309-322. doi: 10.21037/cdt-20-283
17. Hu J., Mondal N.K., Sorensen E. N., Cai L., Fang H.B., Griffith B.P., Wu Z.J. Platelet glycoprotein Ibalpha ectodomain shedding and non-surgical bleeding in heart failure patients supported by continuous-flow left ventricular assist devices // J Heart Lung Transplant. 2014. 33(1.). P. 71-9. doi.org/10.1016/j.healun.2013.08.013
18. Iskakova A.N., Romanova A. A., Aitkulova A. M., Sikhayeva N. S., Zholdybayeva E.V., Ramanculov E.M. Polymorphisms in genes involved in the absorption, distribution, metabolism, and excretion of drugs in the Kazakhs of Kazakhstan // BMC Genet. 2016. 17(23). DOI 10.1186/s12863-016-0329-x
19. Johnson J.A., Gong L., Whirl-Carrillo M., Gage B.F., Scott S.A., Stein C.M., Anderson J.L., Kimmel S.E., Lee M.T., Pirmohamed M., Wadelius M., Klein T.E., Altman R.B. Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and VKORC1 genotypes and warfarin dosing // Clin Pharmacol Ther. 2011. 90(4). P. 625-629. doi:10.1038/clpt.2011.185
20. Kadakia S., Moore R., Ambur V., Toyoda Y. Current status of the implantable LVAD. // Gen Thorac Cardiovasc Surg. 2016. 64(9). P. 501-508.
21. Koliopoulou A., McKellar S.H., Rondina M., Selzman C.H. Bleeding and thrombosis in chronic ventricular assist device therapy: focus on platelets // Curr Opin Cardiol. 2016. 31(3). P. 299-307. doi:10.1097/HCO.0000000000000284
22. Maruo Y., Iwai M., Mori A., Sato H., Takeuchi Y. Polymorphism of UDP - Glucuronosyltransferase and Drug Metabolism // Current Drug Metabolism. 2005. Vol. 6. P. 91-99.
23. Mehra M.R., Crandall D.L., Gustafsson F., Jorde U.P., Katz J.N., Netuka I., Uriel N., Connors J.M., Sood P., Heatley G., Pagani F.D. Aspirin and left ventricular assist devices: rationale and design for the international randomized, placebo-controlled, non-inferiority ARIES HM3 trial // Eur J Heart Fail. 2021. 23(7). P. 1226-1237. doi:10.1002/ejhf.2275
24. Muslem R., Caliskan K., Leebeek F.W.G. Acquired coagulopathy in patients with left ventricular assist devices // J Thromb Haemost. 2018. 16(3). P. 429-440. DOI: 10.1111/jth.13933
25. Netuka I., Pya Y., Bekbossynova M., Ivak P., Konarik M., Gustafsson F., Smadja D. M., Jansen P., Latremouille C. Initial bridge to transplant experience with a bioprosthetic autoregulated artificial heart // J Heart Lung Transplant. 2020. 39 (12). P. 1491-1493. https://doi.org/10.1016/j.healun.2020.07.004
26. Ornelas A., Zacharias-Millward N., Menter D.G., Davis J.S., Lichtenberger L., Hawke D., Hawk E., Vilar E., Bhattacharya P., Millward S. Beyond COX-1: the effects of aspirin on platelet biology and potential mechanisms of chemoprevention // Cancer Metastasis Rev. 2017. 36(2). P. 289-303. DOI 10.1007/s10555-017-9675-z
27. Perera M.A., Cavallari L.H.,Limdi N.A., Gamazon E.R., Konkashbaev A., Daneshjou R., Pluzhnikov A., Crawford D.C., Wang J., Liu N. et al. Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study // The Lancet. 2013. 382(9894). P. 790-796. http://dx.doi.org/10.1016/S0140-6736(13)60681-9
28. Pya Y., Bekbossynova M., Jetybayeva S.,Bekbossynov S., Andossova S., Salov R., Medressova A., Novikova S., Murzagaliyev M. Initial 3-year outcomes with left ventricular assist devices in a country with a nascent heart transplantation program // ESC Heart Fail. 2016. 3(1). P. 26-34. DOI: 10.1002/ehf2.12066
29. Raber I., McCarthy C.P., Vaduganathan M., Bhatt D.L., Wood D.A., Cleland J.G.F., Blumenthal R.S., McEvoy J.W. The rise and fall of aspirin in the primary prevention of cardiovascular disease // The Lancet. 2019. 393(10186). P. 2155-2167. 10.1016/s0140-6736(19)30541-0
30. Saeed O., Colombo P.C., Mehra M.R., Uriel N., Goldstein D.J., Cleveland J., Connors J.M., Najjar S.S., Mokadam N.A., Bansal A., Crandall D., Sood P., Jorde U.P. Effect of aspirin dose on hemocompatibility-related outcomes with a magnetically levitated left ventricular assist device: An analysis from the MOMENTUM 3 study // J Heart Lung Transplant. 2020. 39(6). P. 518-525. https://doi.org/10.1016/j.healun.2020.03.001
31. Santos-Gallego C.G., Badimon J. Overview of Aspirin and Platelet Biology // Am J Cardiol. 2021. Vol. 144. P. S2-S9. https://doi.org/10.1016/j.amjcard.2020.12.018
32. Scherer D., Koepl L.M., Poole E.M., Balavarca Y., Xiao L., Baron J.A., Hsu L., Coghill A.E., Campbell P.T., Kleinstein S.E., Figueiredo J.C. et al. Genetic variation in UGT genes modify the associations of NSAIDs with risk of colorectal cancer: Colon cancer family registry // Genes Chromosomes Cancer. 2014. 53(7). P. 568–578. doi:10.1002/gcc.22167
33. Scott S.A., Khasawneh R., et al. Combined CYP2C9, VKORC1 and CYP4F2 frequencies among racial and ethnic groups // Pharmacogenomics. 2010. 11(6). P. 781-91. doi:10.2217/pgs.10.49
34. Shah R.R. Genotype-guided warfarin therapy: Still of only questionable value two decades on // J Clin Pharm Ther. 2020. 45(3). P. 547-560. DOI: 10.1111/jcpt.13127
35. Sheth H., Northwood E., Ulrich C.M., Scherer D., Elliott F., Barrett J.H., Forman D., Wolf C.R., Smith G., Jackson M.S. et al. Interaction between polymorphisms in aspirin metabolic pathways, regular aspirin use and colorectal cancer risk: A case-control study in unselected white European populations // PLoS ONE. 2018. 13 (2). P. e0192223. DOI: 10.1371/journal.pone.0192223
36. Singhvi A., Trachtenberg B. Left Ventricular Assist Devices 101: Shared Care for General Cardiologists and Primary Care // J Clin Med. 2019. 8 (10). doi:10.3390/jcm8101720
37. Susen S., Rauch A., Van Belle E., Vincentelli A., Lenting P. J. Circulatory support devices: fundamental aspects and clinical management of bleeding and thrombosis // J Thromb Haemost. - 2015. 13 (10). P. 1757-67. DOI: 10.1111/jth.13120
38. Szczuko M., Koziol I., Kotlega D., Brodowski J., Drozd A. The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review // Int J Mol Sci. 2021. 22(21). https://doi.org/10.3390/ ijms222111644
39. Topkara V.K., Knotts R.J., Jennings D.L., Garan A.R., Levin A.P., Breskin A., Castagna F., Cagliostro B., Yuzefpolskaya M. et al. Effect of CYP2C9 and VKORC1 Gene Variants on Warfarin Response in Patients with Continuous-Flow Left Ventricular Assist Devices // ASAIO J. 2016. 62(5). P. 558-64. DOI: 10.1097/MAT.0000000000000390
40. van Oijen M.G., Huybers S., Peters W.H., Drenth J.P., Laheij R.J., Verheugt F.W., Jansen J.B. Polymorphisms in genes encoding acetylsalicylic acid metabolizing enzymes are unrelated to upper gastrointestinal health in cardiovascular patients on acetylsalicylic acid // Br J Clin Pharmacol. 2005. 60(6). P. 623–628. DOI:10.1111/j.1365-2125.2005.02495.x
41. Wadelius M., Chen L. Y., Eriksson N., Bumpstead S., Ghori J., Wadelius C., Bentley D., McGinnis R., Deloukas P. Association of warfarin dose with genes involved in its action and metabolism // Hum Genet. 2007. 121(1). P. 23-34. DOI 10.1007/s00439-006-0260-8
42. Wurtz M., Kristensen S.D., Hvas A.M., Grove E.L. Pharmacogenetics of the Antiplatelet Effect of Aspirin // Current Pharmaceutical Design. 2012. 18(33). P. 5294-5308.
43. Zhalbinova M.R., Rakhimova S.E., Kozhamkulov U.A., Akilzhanova G.A., Kaussova G.K., Akilzhanov K.R., Pya Y. V., Lee J.H., Bekbossynova M.S., Akilzhanova A.R. Association of Genetic Polymorphisms with Complications of Implanted LVAD Devices in Patients with Congestive Heart Failure: A Kazakhstani Study // J Pers Med. 2022. 12 (5). https://doi.org/10.3390/jpm12050744
44. Zhang F., Zhang C., Gu C., Yu Y., Li J. A clinical study of genetic testing to guide the dosing of warfarin after heart valve replacement // BMC Cardiovasc Disord. 2022. 22(183). P. 1-6. https://doi.org/10.1186/s12872-022-02620-x
45. Zimpfer D., Netuka I., Schmitto J.D., Pya Y., Garbade J., Morshuis M., Beyersdorf F., Marasco S., Rao V., Damme L., Sood P., Krabatsch T. Multicentre clinical trial experience with the HeartMate 3 left ventricular assist device: 30-day outcomes // Eur J Cardiothorac Surg. 2016. 50(3). P. 548-54. doi:10.1093/ejcts/ezw169
References: [1-6]
1. Bodaubaj R.I Tajzhanova D.Zh. Geneticheskie prediktory razvitiya restenoza koronarnykh arterii [Genetic predictors of the development of restenosis of the coronary arteries]. West Kazakhstan Medical Journal. 2019. 61(3). pp.163-171. [in Russian]
2. Grinshtejn Ju.I., Kosinova A.A., Grinshtejn I.Ju. Geny-kandidaty rezistentnosti k atsetilsalicilovoi kislote i ikh svyaz' s riskom razvitiya serdechno-sosudistykh katastrof [Candidate genes for resistance to acetylsalicylic acid and their relationship with the risk of developing cardiovascular accidents]. Kardiovaskuljarnaya terapiya i profilaktika [Cardiovascular Therapy and Prevention]. 2013. T. 12. № 1. pp. 67-72. [in Russian]
3. Zhalbinova M.R., Rahimova S.E., Bekbosynova M.S., Andosova S.A., Akil'zhanova A.R. Prichiny i mekhanizmy razvitiya gematologicheskikh oslozhnenii u patsientov s implantirovannym mekhanicheskim ustroistvom levogo zheludochka [Causes and mechanisms of the development of hematological complications in patients with an implanted mechanical device of the left ventricle]. Nauka i Zdravookhranenie [Science & Health]. 2020. 22(1). pp. 5-16. [in Russian]
4. Zhalbinova M.R, Rahimova S.E., Kozhamkulov U.A., Bekbosynova M.S., Akil'zhanova A. Patent № 35979. Sposob podbora i korrektsii dozy aspirina u bol'nykh serdechnoi nedostatochnost'yu s implantirovannym mekhanicheskim ustroistvom levogo zheludochka [Method of selection and correction of aspirin dose in patients with heart failure with implanted mechanical device of left ventricle] No. 2021/0721.1; dec. 11/26/2021; publ. 09.12.2022, Bull. No. 49. [in Russian]
5. Pja, Ju.V., Bekbosynov, S.T., Bekbosynova, M.S., Kuatbaev, E.M., Lesbekov, T.D., Kaliev, R.B., Dzhetybaeva, S.K., Medresova, A.T., Nurmyhametova, Zh.A., Murzagaliev, M.U., et al. Programma transplantatsii serdtsa v epokhu mekhanicheskoi podderzhki krovoobrashheniya: opyt Respubliki Kazakhstan [The program of heart transplantation in the era of mechanical circulatory support: the experience of the Republic of Kazakhstan]. Zhurnal im. akademika B.V.Petrovskogo Klinicheskaya i eksperimental'naya khirurgiya [Journal named after Academician B.V. Petrovsky Clinical and experimental surgery.]. 2017. Tom 5, №3. pp. 49-53. [in Russian]
6. Pja Ju.V., Bekbosynov S.T., Bekbosynova M.S., Medresova A.T., Andosova S.A., et al. Ispol'zovanie sovremennykh ustroistv mekhanicheskoi podderzhki krovoobrashheniya kak al'ternativy transplantatsii serdtsa u patsientov s terminal'noi serdechnoi nedostatochnost'yu [The use of modern mechanical circulatory support devices as an alternative to heart transplantation in patients with terminal heart failure]. Zhurnal im. Akad. B.V. Petrovskogo Klinicheskaya i eksperimental'naya khirurgiya [Journal named after Academician B.V. Petrovsky Clinical and experimental surgery]. 2017. Tom. 5. №1. Pp. 7-14. [in Russian]
Количество просмотров: 539
Категория статей:
Обзор литературы
Библиографическая ссылка
Zhalbinova M.R., Rakhimova S.E., Akilzhanov K.R., Andosova S.A., Bekbosynova M.S., Akilzhanova A.R. Thrombosis and bleeding complications after implantation of mechanical circulatory support devices: the reasons and mechanisms of development, genome-guided correction. Review // Nauka i Zdravookhranenie [Science & Healthcare]. 2023, (Vol.25) 2, pp. 166-174. doi 10.34689/SH.2023.25.2.023Похожие публикации:
UNDERSTANDING OF RECURRENT RESPIRATORY INFECTIONS IN CHILDREN AT THE PRESENT STAGE. REVIEW.
ГЕМОДИНАМИЧЕСКИ ЗНАЧИМЫЙ ОТКРЫТЫЙ АРТЕРИАЛЬНЫЙ ПРОТОК У НЕДОНОШЕННЫХ НОВОРОЖДЕННЫХ ДЕТЕЙ. ОБЗОР ЛИТЕРАТУРЫ
RADIOIODINE-RESISTANT DIFFERENTIATED THYROID CANCER: CLINICOPATHOLOGICAL CHARACTERISTICS, MOLECULAR GENETIC ALTERATIONS. REVIEW.
ПРЕРЫВИСТАЯ КАТЕТЕРИЗАЦИЯ МОЧЕВОГО ПУЗЫРЯ КАК «ЗОЛОТОЙ СТАНДАРТ» ЛЕЧЕНИЯ НЕЙРОГЕННОГО МОЧЕВОГО ПУЗЫРЯ У ЛИЦ, С ПОВРЕЖДЕНИЕМ СПИННОГО МОЗГА
АНАЛИЗ ОПЫТА МЕДСЕСТЕР И ФАКТОРОВ, ВЛИЯЮЩИХ НА ДОБРОВОЛЬНОЕ СООБЩЕНИЕ ОБ ИНЦИДЕНТАХ